GlassScriptPhysician profile
Anthony C Passarella
NPI 1942762778
$1,318.15
in general payments reported to CMS, 2019-2025
12 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $118 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $335.23 | 2025 | Tremfya |
| Gilead Sciences, INC. | $174.66 | 2025 | Livdelzi |
| Janssen Scientific Affairs, LLC | $148.91 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2025 | |
| Mallinckrodt Hospital Products INC. | $123.35 | 2025 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $111.82 | 2025 | Voquezna |
| Abbvie INC. | $58.66 | 2025 | |
| Genzyme Corporation | $35.17 | 2025 | |
| Madrigal Pharmaceuticals | $31.78 | 2025 | Rezdiffra |
| Lilly USA, LLC | $20.79 | 2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $18.03 | 2025 | Gattex |
| Celltrion USA INC. | $16.67 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Passarella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.